AIM Vaccine's mRNA shingles vaccine gets US FDA approval for clinical trials

Shares of AIM Vaccine (6660) once jump as much as 6.7 percent to HK$4.32 during Monday morning trading following the announcement that one of its vaccines has received approval from the US Food and Drug Administration.

The company disclosed that its mRNA shingles vaccine was recently granted Investigational New Drug approval by the FDA. 

This marks AIM Vaccine's second innovative vaccine to enter clinical trials in the US.

STAFF REPORTER